RESULTS ROUND-UP: Abiomed impresses with Impella; exchange rate woe for Alere, Qiagen, Tornier
This article was originally published in Clinica
Executive Summary
Abiomed’s share price surged 16% as it reported a strong fourth quarter and increased its guidance. Q4 revenues of $67.6m increased 34% year-on-year and exceeded the $62m predicted by Jefferies analyst Raj Denhoy.